ANDOVER, Mass. & HAIFA, Israel–(BUSINESS WIRE)–MeMed, a global leader in host-response diagnostics, today announced a major milestone: more than 100,000 patients have now been tested with MeMed BV®, the company’s flagship diagnostic that accurately distinguishes between bacterial and viral infections in just 15 minutes, based on the body’s immune response. This milestone highlights MeMed’s commitment to advancing precision medicine, empowering responsible antibiotic use by care providers, and transforming infection management across diverse care settings.

Read more here.